DDInter364 DDInter915
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Chlorpropamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dyspnoea {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glyburide
Glyburide {u} (Compound) upregulates {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Chlorpropamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Chlorpropamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Indacaterol (Compound)
Chlorpropamide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Indacaterol (Compound)
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Chlorpropamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Indacaterol (Compound)
Chlorpropamide (Compound) resembles Glyburide (Compound) and Glyburide (Compound) upregulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)
Chlorpropamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)